OTC MOVES AGAIN

Major Houston energy conference once again postponed due to COVID-19

OTC has been delayed again due to the pandemic. OTC/Facebook

This year, thousands of visitors from some 100 countries around the world were expected to descend on NRG Center for the annual Offshore Technology Conference. But like so many major in-person happenings, the event has been again postponed due to the pandemic, organizers announced.

Often dubbed the "South by Southwest for offshore" by insiders, the massive expo had initially been postponed to May 3-6, 2021, as CultureMap previously reported. But on November 16, the OTC's board of directors announced a new schedule: August 16-19, 2021. The move is "due to the ongoing challenges presented by COVID-19 and out of the greatest care for the health and safety of our partners, attendees, exhibitors, staff, and community," per a press release.

The OTC board added, in a statement:

In the coming weeks, OTC will be communicating with authors, speakers, exhibitors, and partners to develop new in-person and virtual plans and ensure the conference continues to provide a platform for energy professionals to meet and exchange ideas.

By postponing OTC to the second half of 2021, we aim to preserve the significant work of the program committee and authors, as well as minimize the economic impact this decision has on businesses in Houston and throughout the industry.

A mainstay since 1969, the conference is a significant boon to the local economy, as industry regulars, investors, and entrepreneurs pack our hotels, restaurants, and entertainment venues. The OTC has spawned OTC Brazil, OTC Asia, and even the Arctic Technology Conference.

Two years ago, more than 60,000 attendees and 2,300 exhibitors packed the event.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted